COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

CPTAC At AACR Virtual Meeting II

We are so excited to be a part of the AACR Virtual Meeting II, June 22-24, 2020! Join us for our Clinical Proteomic Tumor Analysis Consortium (CPTAC) Educational Session: Resources and Data Dissemination Tuesday June 23rd, 3:00-5:00 p.m. Our distinguished researchers will share about CPTAC's comprehensive proteomic and matching genomic tumor characterization methodologies, computational analyses, and production of community resources, particularly in the context of clinical trials. Recent advances on mass spectrometry-based targeted assays for inclusion in clinical trials will also be discussed.

Our speakers for the Educational Session include:

  • Steven A. Carr. Broad Inst. of MIT and Harvard, Cambridge, MA  
  • Shankha Satpathy. Broad Institute of MIT and Harvard, Boston, MA  
  • Bing Zhang. Baylor College of Medicine, Houston, TX  
  • Amanda G. Paulovich. Fred Hutchinson Cancer Research Center, Seattle, WA  
  • Matthew J. Ellis. Baylor College of Medicine, Dan L. Duncan Cancer Center, Houston, TX  

Also 'stop by' our Virtual Posters any time during the meeting:

  • PO.CH03.01 Proteomics and Biomarker Discovery
  • PO.TB02.02 Developmental Pathways in Cancer
  • PO.ET04.04 Molecular Classification of Tumors for Diagnostics, Prognostics and Therapeutic Outcomes 1
  • PO.ET04.05 Molecular Classification of Tumors for Diagnostics, Prognostics and Therapeutic Outcomes 2
  • PO.MCB09.01 Functional Genomics and Other Topics
  • PO.MCB09.02 Large-Scale and High-throughput Sequencing
  • PO.BSB01.03 Knowledge, Networks, Graphs, and Models for Discovery
  • PO.BSB01.05 Multi-omic and Multimodal Discovery
  • PO.BSB02.03 Network Biology / Multi-omics
  • LBPO.CH01 Late-Breaking Research: Cancer Chemistry

Register here for free - look for the big, green button!

The CPTAC program uses proteogenomic methods to analyze layers of proteomic and genomic tumor information to reveal new biology.  These findings help researchers to explore, characterize, and effectively target cancer for both biological and clinical use and is a part of NCI’s Office of Cancer Clinical Proteomics Research (OCCPR).

OCCPR aims to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advancing proteome/proteogenome science and technology development through community resources (data and reagents), and accelerating the translation of molecular findings into the clinic.